Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman

BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT) Following Mgmt. Meeting

August 7, 2025 11:05 AM EDT

BMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $50.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "We hosted an investor call with management post 2Q earnings and takeaways include: (1) Management resumed Elevidys infusions following the pause (first infusion on 8/5)... More